Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
LMO7-ALK fusion
i
Other names:
LMO7, LIM Domain 7, FBX20, F-Box Only Protein 20, KIAA0858, FBXO20, LIM Domain Only Protein 7, LMO-7, LOMP, Zinc-Finger Domain-Containing Protein, LIM Domain Only 7 Protein, F-Box Protein Fbx20, LIM Domain Only 7, LMO7b, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
;
4008
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK positive (74)
ALK negative (4)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
ALK positive (74)
ALK negative (4)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
LMO7-ALK fusion
Non Small Cell Lung Cancer
LMO7-ALK fusion
Non Small Cell Lung Cancer
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
alectinib
Resistant: C3 – Early Trials
alectinib
Resistant
:
C3
LMO7-ALK fusion
Non Small Cell Lung Cancer
LMO7-ALK fusion
Non Small Cell Lung Cancer
crizotinib + ensartinib
Sensitive: C3 – Early Trials
crizotinib + ensartinib
Sensitive
:
C3
crizotinib + ensartinib
Sensitive: C3 – Early Trials
crizotinib + ensartinib
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.